Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51 results about "Posaconazole" patented technology

Posaconazole is used to prevent certain fungal infections in patients who have severely weakened immune systems (such as patients who have had chemotherapy).

Methods of treatment

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.
Owner:BOW RIVER LLC

Methods of treatment

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
Owner:BOW RIVER LLC

Posaconazole dry powder inhalant and preparation method thereof

The invention provides a posaconazole dry powder inhalant and a preparation method thereof, and relates to the technical field of medicine preparation. The posaconazole dry powder inhalant provided by the invention comprises posaconazole, a space stabilizer and a surfactant, has excellent aerodynamic performance, good redispersibility, higher solubility and dissolution rate and excellent antifungal activity, and in-vivo pharmacokinetic evaluation shows that the lung concentration is higher and the whole-body exposure is lower. The posaconazole dry powder inhalant is prepared by adopting a wet medium grinding and spray drying technology, and a nanocrystal technology is combined with pulmonary administration, so that the obtained posaconazole dry powder inhalant has excellent aerodynamic performance, good redispersibility, higher solubility and dissolution rate, and can be used for preparing a medicine for preventing and treating diseases. And a strategy with a wide prospect is provided for targeted delivery of a drug with poor solubility to an infected part deep in the lung.
Owner:GUANGZHOU CHUANGRONG BIOTECHNOLOGY CO LTD

Posaconazole ethosome and preparation method thereof

The invention provides a posaconazole ethosome and a preparation method thereof, posaconazole is encapsulated in ethosome, and the posaconazole ethosome is composed of the following components by weight: 0.1-5% of posaconazole, 0.1-5% of posaconazole, 0.1-5% of posaconazole, 0.1-5% of posaconazole, and the balance of ethanol. 1-8% of phospholipid; 0%-0.5% of cholesterol; 20%-45% of ethanol; 0-0.1% of an antioxidant; 0%-0.5% of a nonionic surfactant; and 40.9 to 78.9 percent of water. The invention has the characteristics of high encapsulation efficiency, uniform particle size distribution and no irritation to skin. And the ethosome can load both water-soluble drugs and fat-soluble drugs, and has the advantages of simple composition, high encapsulation efficiency, uniform particle size distribution, no skin irritation, simple preparation and the like.
Owner:ZHUOHE PHARM GRP CO LTD

Method for rapidly determining blood concentration of posaconazole and application

The invention relates to the technical field of medical examination, and discloses a method for rapidly measuring the blood concentration of posaconazole and application of the method. According to the method for rapidly determining the blood concentration of posaconazole and the application of the method, compared with chromatography in the prior art, the adopted mobile phase is relatively single, the configuration time of the mobile phase is saved, and meanwhile, the fluctuation of a detection result caused by the configuration of the mobile phase is reduced to the greatest extent; the stability of the method is further enhanced; meanwhile, compared with other liquid chromatography methods, the detection method has the advantages that the single-needle sample injection time is short, the reagent preparation is simple, no endogenous and common exogenous substance interference exists around the target peak of posaconazole, and the like, and the detection efficiency and the accuracy of the detection result are improved.
Owner:JIANGXI PROVINCIAL PEOPLES HOSPITAL

Gastro-resistant high-strength formulation containing posaconazole

A gastro-resistant high-strength unit dosage form includes a solid solution prepared by hot-melt extrusion, whereby the solid solution contains 300 mg posaconazole and an enteric polymer in a specific weight ratio. The unit dosage form may be a capsule or an optionally film-coated tablet.
Owner:ALFRED E TIEFENBACHER (GMBH & CO KG)

Nanostructured lipid carrier based composition of poorly soluble Anti-fungal agent

The present invention relates to stable lipidic drug delivery system pharmaceutical composition of poorly soluble anti-fungal drug substance suitable for administration for the prophylaxis and treatment of fungal infection. The present invention particularly relates to stable pharmaceutical composition of poorly soluble tri-azole anti-fungal (TAAF) drug substance posaconazole by improving the dissolution and bioavailability to achieve desirable pharmacokinetic, improved patient compliance and reduced overall cost of therapy.
Owner:RITESHKUMAR BALDEVBHAI GURJAR +1

Preparation Method of Posaconazole Starting Material SM3

The present invention relates to the technical field of drug intermediate synthesis, and particularly relates to a preparation method of posaconazole starting material SM3. CeCl3·7H2O and sodium borohydride are added to compound POS-1 for an asymmetric reduction reaction to obtain compound POS-2. Compound POS-2 reacts with 3,5-bis(trifluoromethyl)benzenesulfonyl chloride to obtain compound POS-3. Hydrazine hydrate attacks from the back of compound POS-3 with a larger steric hindrance to undergo an SN2 reaction to obtain a stereoselectively specific compound POS-4. Compound POS-4 then reacts with ethyl formate and forms a salt with oxalic acid to obtain the product posaconazole starting material SM3. By means of asymmetric reduction of carbonyl groups and selective nucleophilic substitution, the present invention effectively avoids the chiral resolution step, thereby reducing the content of isomeric impurities. The prepared product not only has a high ee value, but also the yield is significantly improved, thereby greatly reducing the production cost.
Owner:SHANDONG JINCHENG KERUI CHEMICAL CO LTD +1

Application of azole medicine in preparation of antifungal medicine

The invention relates to application of azole drugs in preparation of antifungal drugs, and belongs to the technical field of research and development of antifungal drugs. According to the application of the glycyrrhetinic acid combined with the azoles in preparation of the antifungal drugs, the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole shows a good synergistic effect or antagonistic effect on aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans, and the application of the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole in preparation of the antifungal drugs is disclosed. And a research and development direction is provided for preparing medicines for resisting aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans.
Owner:JINGZHOU CENT HOSPITAL (JINGZHOU HOSPITAL AFFILIATED TO YANGTZE UNIV)

Methods of treatment

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.
Owner:BOW RIVER LLC

Application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and antifungal drugs

The application discloses application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and the antifungal drugs, and relates to the technical field of antifungal drugs. It is found through systematic in-vitro drug sensitivity test that natural product gynostemma pentaphyllum saponin H combined with specific azole antifungal drugs (especially posaconazole POS) can produce significant synergistic antifungal effect, especially for clinical thorny aspergillus, candida, new cryptococcus and dark fungi. The combination strategy can significantly reduce the minimum inhibitory concentration of azole drugs, reverse drug resistance, and is effective for multi-drug resistant strains (such as candida auris). The application provides an efficient and low-toxicity new combination drug scheme for overcoming the increasingly serious fungal drug resistance problem.
Owner:JINGZHOU CENT HOSPITAL (JINGZHOU HOSPITAL AFFILIATED TO YANGTZE UNIV)

In-vitro dissolution method of posaconazole enteric-coated tablet

The invention discloses an in-vitro dissolution method of a posaconazole enteric-coated tablet, which is characterized in that a Tween-80 (TWEEN-80) surfactant is added into a dissolution medium, so that the solubility of the posaconazole enteric-coated tablet in a phosphate buffer solution is remarkably improved, the phenomenon that a solution in a dissolution cup is not uniform is solved, the jump point phenomenon of a dissolution curve is eliminated, and the dissolution rate of the posaconazole enteric-coated tablet is improved. When a phosphate buffer solution added with a certain amount of surfactant is used as a dissolution medium, the accumulated dissolution amount at each time point is stable, the dissolution curve is smooth, the detection result is accurate and reliable, the repeatability and predictability of the dissolution test are remarkably improved, and a more reliable detection method is provided for the initial stage of drug research and development and quality control.
Owner:WUXI FORTUNE PHARMA

Ophthalmic antifungal phospholipid complex solution containing posaconazole and preparation method of ophthalmic antifungal phospholipid complex solution

The invention relates to an ophthalmic antifungal phospholipid complex solution containing posaconazole. The ophthalmic antifungal phospholipid complex solution comprises at least one of an anionic phospholipid complex solution, a neutral phospholipid complex solution and a cationic phospholipid complex solution, when the solution is an anionic phospholipid complex solution, the posaconazole, phospholipid, beta-sitosterol, a hydrated buffer solution and an organic solvent are mixed according to a ratio of 10 mg of posaconazole, 20-200 mg of phospholipid, 20-120 mg of beta-sitosterol, 5-20 mL of the hydrated buffer solution and 1-20 mL of the organic solvent; when the solution is a neutral phospholipid complex solution, the posaconazole and phospholipid complex solution is prepared from the following components in proportion: 10 mg of posaconazole, 17.5 to 170 mg of phospholipid, 20 to 120 mg of beta-sitosterol, 2.5 to 30 mg of DSPE-PEG2000, 5 to 20 mL of hydrated buffer solution and 1 to 20 mL of organic solvent; when the solution is a cationic phospholipid complex solution, the following components are proportioned: 10 mg of posaconazole, 17.5 to 170 mg of phospholipid, 20 to 120 mg of beta-sitosterol, 2.5 to 30 mg of DSPE-PEG2000, 20 to 70 mg of a cationic material, 5 to 20 mL of a hydration buffer solution and 1 to 20 mL of an organic solvent. The penetrating power of the phospholipid complex solution in cornea can be remarkably improved, and the effect of treating fungal keratitis is remarkable.
Owner:HENAN UNIVERSITY

A preparation method of posaconazole intermediate

The present invention provides a preparation method of a posaconazole intermediate. In this method, 3-pentanone is used as the starting material, and the posaconazole intermediate is prepared through an asymmetric catalytic oxidation reaction, a substitution reaction and an asymmetric reductive amination reaction. The product obtained by this method has high purity and good yield. The preparation method has fewer steps, the raw materials are cheap and easily available, the operation is simple, the total yield is high, and it is more suitable for industrial production.
Owner:LIANYUNGANG GUIKE PHARMA

Preparation method of key intermediate diol olefin compound of posaconazole

The invention discloses a preparation method of a posaconazole key intermediate diol olefin compound, which comprises the following steps: dissolving a compound 1 in an organic solvent A, adding a mixed solution of an additive and an organic solvent B, alkali a and trioxymethylene, continuing to react, and treating to obtain a compound 2; dissolving the obtained compound 2 in an organic solvent C, adding a reducing agent, and performing heating reflux reaction to obtain a compound I; the synthesis route is as follows: the reaction process is simple, the raw materials are simple and easy to obtain, harsh reaction conditions are not needed, the route is simple and convenient, the reaction operation is simple, and the drug development potential is achieved.
Owner:ZHEJIANG UNIV OF TECH

Cocrystals of posaconazole, methods of making and using same

The disclosure generally relates to cocrystals of posaconazole and a coformer. The disclosure further relates to pharmaceutical compositions comprising the cocrystals, as well as methods of making the cocrystals, and methods of treating or preventing fungal, yeast, or dermatophyte infections using the cocrystals.
Owner:THE RGT UNIV OF MICHIGAN

Carbonyl reductase mutant and application thereof in synthesis of posaconazole intermediate

The invention discloses a carbonyl reductase mutant and application of the carbonyl reductase mutant in synthesis of a posaconazole intermediate. The mutant protein is a non-natural protein, and the mutant protein can significantly improve the activity of catalyzing reduction of carbonyl in (S)-2-benzyloxy-3-pentanone to generate R-configuration alcohol. When the carbonyl reductase mutant strain with improved activity is applied to the production process of a posaconazole intermediate, 100-200 g / L of a substrate can be completely converted, and (2S, 3R)-2-benzyloxy-3-pentanol is generated.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Methods of treatment

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 3 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 3-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 3-42 days.
Owner:BOW RIVER LLC

Posaconazole fatty acid ester, posaconazole fatty acid ester fat emulsion and preparation method of posaconazole fatty acid ester fat emulsion

The invention discloses posaconazole fatty acid ester, posaconazole fatty acid ester fat emulsion and a preparation method of the posaconazole fatty acid ester fat emulsion, and belongs to the technical field of pharmaceutical preparations. The solubility of the posaconazole fatty acid ester provided by the invention in the oil for injection is remarkably improved, and the posaconazole fatty acid ester can be effectively applied to subsequent preparation of the posaconazole fatty acid ester fat emulsion. Meanwhile, by selecting components in a proper mass percentage range for mutual cooperation, the obtained posaconazole fatty acid ester fat emulsion is small in average particle size, and the pH value and the osmotic pressure are close to those of human plasma, so that the posaconazole fatty acid ester fat emulsion has excellent intravenous injection safety and can be effectively applied to preparation of antifungal injection. In addition, the preparation methods of the posaconazole fatty acid ester and the posaconazole fatty acid ester fat emulsion provided by the invention are simple to operate and beneficial to actual large-scale production.
Owner:MITSUBISHI PHARMA GUANGZHOU +1

Methods of treatment with CYP3a4 substrate drugs

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
Owner:BOW RIVER LLC

Carbonyl reductase mutants and their applications in the synthesis of posaconazole intermediates

The present invention discloses a carbonyl reductase mutant and its application in the synthesis of posaconazole intermediates. The mutant protein is a non-natural protein and has significantly improved catalysis ( S )-2-benzyloxy-3-pentanone is reduced to form R The carbonyl reductase mutant strain with enhanced activity in the present invention is applied to the production process of posaconazole intermediates, and 100-200 g / L substrate can be completely converted to produce (2 S ,3 R )-2-benzyloxy-3-pentanol.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Method for synthesizing posaconazole intermediate (2S)-2-benzyloxy-3-pentanone

The invention discloses a method for synthesizing a posaconazole intermediate (2S)-2-benzyloxy-3-pentanone. The method comprises the following steps: dropwise adding piperidine into S-methyl lactate, and carrying out amine ester exchange reaction to generate (S)-2-hydroxy-1-(1-piperidyl)-1-acetone; the preparation method comprises the following steps: carrying out benzyl protection on (S)-2-hydroxy-1-(1-piperidyl)-1-acetone to obtain (2S)-2-(benzyloxy)-1-(1-piperidyl)-1-acetone, then adding the (2S)-2-(benzyloxy)-1-(1-piperidyl)-1-acetone into a Grignard reagent, cooling for reaction, and after the reaction is finished, adding an ice water and hydrochloric acid mixed solution for quenching reaction to obtain (2S)-2-benzyloxy-3-pentanone. According to the method, the S-methyl lactate and the piperidine are used as raw materials, the price of the piperidine is lower than that of tetrahydropyrrole in the prior art, the reaction time for obtaining products with the same yield and purity is greatly shortened, the production period can be shortened, the production efficiency is higher, and the production cost is lower.
Owner:BEIJING LIANBEN TECH CO LTD

Synergistic antifungal composition and method

This invention provides a method for inhibiting the growth of a pathogenic mold by contacting the pathogenic mold with a synergistically effective amount of an NK1 antagonisfand an antifungal agent. This invention also provides a method for inhibiting the growth of a mammalian fungal pathogen by contacting the mammalian fungal pathogen with a synergistically effective amount of posaconazole and rolapitant. In some aspects, the mammalian fungal pathogen is a species of Candida (e.g., C. glabrata, C. auris, C. albicans, C. dubliniensis, or C. parapsilosis). Aspergillus, Cryptococcus, Mucor, orRhizopus. In addition, A surface disinfectant comprising a synergistic amount of an NK1 antagonist and an antifungal agent in admixture with a carrier or excipient.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC

Methods of treatment with CYP3a4 substrate drugs

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
Owner:BOW RIVER LLC

Posaconazole-containing solid dispersion and posaconazole-containing formulation containing the same

PendingJP2026135933ACelluloseEthylic acid
One embodiment of the present invention provides a posaconazole-containing solid dispersion that suppresses the delayed dissolution of posaconazole during the storage period after manufacturing or the period until administration of a posaconazole-containing formulation. Alternatively, one embodiment of the present invention provides a posaconazole-containing formulation in which the delayed dissolution of posaconazole during the storage period after manufacturing or the period until administration is suppressed. [Solution] A posaconazole-containing solid dispersion according to one embodiment of the present invention comprises posaconazole, hypromellose acetate succinate, and hydroxypropyl cellulose having a viscosity of 6 mPa·s or more and 10 mPa·s or less in a 2% aqueous solution at 20°C and an average molecular weight of 140,000.
Owner:SAWAI PHARMA

Hybridoma cell strain secreting isavuconazole monoclonal antibody and application thereof

The invention relates to a hybridoma cell strain secreting an isavuconazole monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the isavuconazole, the IC50 value of the monoclonal antibody to the isavuconazole is 13.317 ng / mL, and the IC50 value of the monoclonal antibody to the structural analogue of the isavuconazole is 13.317 ng / mL. According to the present invention, the low-concentration isavuconazole, such as fluconazole, ketoconazole, posaconazole, clotrimazole, miconazole, econazole, voriconazole, bifenconazole, luliconazole and sertaconazole, does not have the cross reaction, and the cross reaction rate is less than 1%, such that the low-concentration isavuconazole can be accurately detected.
Owner:WUXI DITENGMIN BIOTECHNOLOGY CO LTD

In situ ready-to-use injection formulations of posaconazole free of cyclodextrin and its derivatives

The present disclosure relates to an in situ ready-to-use injection formulation of posaconazole free of cyclodextrin and derivatives of cyclodextrin, which can be formulated in situ as a nanosuspension injection of posaconazole by a simple dilution operation during clinical use. The formulation has no adverse effects on the renal function of patients, no extreme pH, and low vascular irritation, and can be administrated without the need for central venous cannulation during clinical use. The present disclosure also relates to a method for preparing the formulation and the use of the formulation in the treatment and prevention of fungal infections.
Owner:HEFEI COSOURCE PHARMA CO LTD

Synthesis method of posaconazole key intermediate

The invention provides a preparation method of a posaconazole key intermediate I. The method comprises the following steps: by taking a compound II as a raw material, carrying out chiral catalytic substitution reaction to obtain a compound III, carrying out bromination and cyclization on dibromohydantoin to obtain a compound IV, and hydrolyzing to obtain the target compound I. The compound is the key intermediate of an antifungal drug posaconazole. The method disclosed by the invention is simple to operate, mild in condition, high in reaction yield, obviously reduced in cost, more environment-friendly and suitable for large-scale industrial production. # imgabs0 #
Owner:BEIJING LIANBEN TECH CO LTD